Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the
U.s. Cardiac Troponin Market
Request Now !
Cardiac markers are used as traceable substances while diagnosing patients with chest pain and suspected acute coronary syndrome (ACS). Cardiac troponins are one of the cardiac biomarkers or diagnostic markers centralized to myocardial infarction or heart muscle cell death diagnosis. Troponin is found in skeletal muscle and cardiac muscle of human body, thus increased level of the cardiac troponin circulating in the blood represents the susceptibility of myocardial infarction.
The growth of the U.S. cardiac troponin market is driven by increase in demand for cardiac biomarkers for cardiovascular disease diagnosis, rise in incidence of acute coronary syndrome (ACS), advancements in the cardiac biomarkers, and growth in demand for point-of-care cardiac testing kits. High specificity and sensitivity of these markers to detect any cardiac disorders and development of new products by the key market players contribute towards the market growth.
However, factors such as limited reimbursements and lack of precision while collecting sample impede the market growth. The development of multi-assay biomarkers and increase in awareness of cardiac troponin biomarkers in developing countries are expected to supplement the market growth in the near future.
The U.S. cardiac troponin market is segmented on the basis of product, application, and end user. Based on product, the market is categorized into cTn T, cTn I, and TnC. Applications covered in the study include acute coronary syndrome, myocardial infarction, congestive heart failure, and others. By end user, the market is bifurcated into laboratory testing and point of care testing.
The major players operating in this market include Abbott Diagnostics, Inc., F. Hoffmann-La Roche Ltd, bioMrieux SA, BG Medicine, Inc., Ortho-Clinical Diagnostics, Inc., Singulex, Inc., Alere, Inc., Siemens Healthcare Diagnostics, Inc., Beckman Coulter, Inc., and LifeSign LLC.
- The study provides an in-depth analysis of the U.S. cardiac troponin market with current trends and future estimations to elucidate the imminent investment pockets.
- The report provides information about the current and upcoming trends in the global biologic response modifiers market from 2016 to 2023, which helps to determine the prevailing opportunities.
- Comprehensive analysis of factors that drive and restrict the growth of the U.S. cardiac troponin market is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
- Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the U.S. cardiac troponin market.
U.S. Cardiac Troponin Market key Segments:
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others Applications
By End User
- Laboratory Testing
- Point-of-care Testing
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
CHAPTER 4 UNITED STATES CARDIAC TROPONIN MARKET, BY PRODUCT TYPE
4.1.1. Market size and forecast
4.2. CTN T
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. CTN I
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 UNITED STATES CARDIAC TROPONIN MARKET, BY APPLICATIONS
5.1.1. Market size and forecast
5.2. ACUTE CORONARY SYNDROME
5.2.1. Market size and forecast
5.3. MYOCARDIAL INFARCTION
5.3.1. Market size and forecast
5.4. CONGESTIVE HEART FAILURE
5.4.1. Market size and forecast
5.5.1. Market size and forecast
CHAPTER 6 UNITED STATES CARDIAC TROPONIN MARKET, BY END-USERS
6.1.1. Market size and forecast
6.2. LABORATORY TESTING
6.2.1. Market size and forecast
6.3. POINT OF CARE TESTING
6.3.1. Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. F. HOFFMANN-LA ROCHE LTD
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. BIOMÉRIEUX SA
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. ROCHE HOLDING AG
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. ORTHO-CLINICAL DIAGNOSTICS, INC.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. SINGULEX, INC.
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. ALERE, INC.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. SIEMENS HEALTHCARE DIAGNOSTICS, INC.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. BECKMAN COULTER, INC.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. LIFESIGN LLC
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
With collective industry experience of about 200 years of its analysts and experts, Allied
Market Research (AMR)
encompasses most infallible research methodology for its market intelligence and industry
analysis. We do not only
engrave the deepest levels of markets but also sneak through its slimmest details for the
purpose of our market estimates
and forecasts. Our approach helps in building greater market consensus view for size, shape and
industry trends within
each industry segment. We carefully factor in industry trends and real developments for
identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data,
expert views and analysis
and high value independent opinions. Our research process is designed to deliver balanced view
of the global markets and
allow stakeholders to make informed decisions.
We offer our clients exhaustive research and analysis based on wide variety of factual inputs,
which largely include interviews with industry participants, reliable statistics and regional
intelligence. Our in-house industry experts play instrumental role in designing analytic tools
and models, tailored to the requirements of particular industry segment. These analytical tools
and models sanitize the data & statistics and enhance the accuracy of our recommendations
and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology,
our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be
referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most
reliable and guarantees sound business planning.
We refer a broad array of industry sources for our secondary, which typically include; however,
not limited to:
Company SEC filings, annual reports, company websites, broker & financial reports and
investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press
releases for market estimates and forecast
Our primary research efforts include reaching out participants through mail, tele-conversations,
referrals, professional networks and face-to-face interactions. We are also in professional
corporate relations with various companies that allow us greater flexibility for reaching out
industry participants and commentators for interviews and discussions, fulfilling following
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced
industry members. These participants include; however, not limited to:
Analyst tools and models
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level
distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
AMR has developed set of analyst tools and data models to supplement and expedite the analysis
process. Corresponding to markets, where there is significant lack of information and estimates,
AMR’s team of experts and analyst develop specific analyst tools and industry models to
translate qualitative and quantitative industry indicators into exact industry estimates. These
models also allow analysts to examine the prospects and opportunities prevailing in the market
to accurately forecast the course of the market.